SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation on December 20, 2018, reporting events occurring on December 19, 2018. The filing details the entry into a Material Definitive Agreement with Nestec Ltd. regarding the exclusive supply of nicotinamide riboside (NR) marketed under the brand name Tru Niagen.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. Instead, it outlines the financial terms of the new Supply Agreement:
- Upfront Fee: $4,000,000 payable by Nestec to ChromaDex.
- Launch Fees: Potential aggregate payment of $6,000,000 upon the launch of the first Approved Product in each sub-Territory for medical nutrition and functional food/beverage categories.
- Sales Fees: Tiered percentage rates ranging from low-single digit to high-single digit percent of worldwide annual net sales of Approved Products.
- Minimum Annual Royalty: Applicable starting 24 months after the launch of an Approved Product in the relevant category.
- Termination Fees: $500,000 per Product Category if Nestec terminates between the first anniversary and the 24th month after launch.
Material Changes and Strategic Developments
The primary material change is the establishment of an exclusive supply relationship with Nestec for NR in specific categories (medical nutritional and functional food/beverage) across North America, Europe, Latin America, Australia, New Zealand, and Japan. Under the agreement, ChromaDex is restricted from selling NR to third parties or using it in medical nutritional products within these territories, subject to reversion rights. ChromaDex retains co-exclusive rights for protein-based ready-to-drink or loose powder beverages.
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The agreement positions ChromaDex to monetize its NR technology through a major global partner, with revenue potential tied to product launches and sales volume.
Risks and Contingencies:
- Technical Feasibility: Nestec may terminate the agreement without penalty if technical feasibility in desired food forms is not achieved by June 30, 2019.
- Termination Rights: Nestec has multiple exit options, including termination for cause, bankruptcy, force majeure, or specific time-based terminations with or without fees.
- Patent Expiration: Sales fees will cease upon the expiration or abandonment of all applicable issued patents and filed patent applications for NR.
- Inventory Wind-down: Upon termination, Nestec may sell inventory for six months but loses all rights thereafter.
Key Facts for Investor Verification
- Verify the receipt and accounting treatment of the $4,000,000 upfront fee in the upcoming 10-K filing.
- Monitor the June 30, 2019 deadline for Nestec's technical feasibility assessment, which poses a risk of early termination.
- Confirm the specific tiered royalty percentages and minimum annual royalty thresholds in the full redacted agreement filed as an exhibit to the 10-K.
- Track the launch dates of the first Approved Products in each sub-Territory to trigger the potential $6,000,000 in launch fees.
- Review the status of ChromaDex's patent portfolio for NR to understand the duration of royalty eligibility.